DIA to Shine Light on Newly Released PCAST Report
“Reinventing the R&D Business Model: Heeding the President’s PCAST Report on
Innovation” to Be Hosted by the Tufts Center for the Study of Drug Development
HORSHAM, Pa. -- April 17, 2013
A consummate group of moderators and panelists will participate in an
executive session at DIA’s 2013 49th Annual Meeting: Advancing Therapeutic
Innovation and Regulatory Science. The session, to be held on June 25 in
Boston, will be hosted by the Tufts Center for the Study of Drug Development
(CSDD) and focus on a report released in January by the President’s Council of
Advisors on Science and Technology (PCAST). Included in the panel will be
Bernard Munos, founder of InnoThink Center for Research in Biomedical
Innovation, who was recently noted in FierceBiotech as one of the 25 most
influential people in biopharma, and Dalvir Gill, CEO of TransCelerate
With the landscape for biopharmaceuticals rapidly changing, this senior-level
session will examine how companies across the pharmaceutical sector are
transforming their R&D business models to meet current and future market
demands. Along with R&D, the panel will address preclinical, clinical,
regulatory, operations, portfolio management and marketing issues—all aspects
of business development.
Susan Cantrell, director of DIA North America, said, “We are truly honored to
have this panel, whose members bring unparalleled experience, expertise and
thought leadership. With the insight of these esteemed panelists, we are
certain this interactive session will provide invaluable information that will
help companies to move their businesses forward. Their views and discussion of
the PCAST report come at an exciting time as the country seeks to lead the
world in health care innovation.”
The moderators and panelists include:
*Kenneth I. Kaitin, Ph.D.
Professor and Director, CSDD
Tufts University School of Medicine
*Kenneth A. Getz, MBA
Director of Sponsored Research, Tufts CSDD; Chairman, Center for
Information and Study on Clinical Research Participation
DIA Chairman, 2011
*Bernard Munos, MBA
InnoThink Center for Research in Biomedical Innovation
*Tomasz Sablinski, M.D.
Founder and CEO
Transparency Life Sciences
*Robert J. Franco, Ph.D.
*Andy Lee, M.D.
Senior Vice President, Global Clinical Operations
*Dalvir Gill, Ph.D.
TransCelerate Biopharma Inc.
Visit www.diahome.org/DIA2013 to learn more about DIA’s 2013 49th Annual
Meeting. To schedule an interview with one of the panelists or to request a
press credential, please contact Eric Rosen at firstname.lastname@example.org or at
ABOUT DIA: DIA is a neutral, global, professional and member-driven
association of nearly 18,000 professionals involved in the discovery,
development and life cycle management of pharmaceuticals, biotechnology,
medical devices and related health-care products. Through our international
educational offerings and myriad networking opportunities, DIA provides a
global forum for knowledge exchange that fosters the innovation of
products,technologies and services to improve health and well-being
worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel,
Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C. and
Latin America. Visit our website at www.diahome.org and follow DIA at:
LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest.
Eric Rosen, 215-290-9153
Press spacebar to pause and continue. Press esc to stop.